Correction: Toward an understanding of the structural basis of allostery in muscarinic acetylcholine receptors
2024
Correction on Xanomeline and Alzheimer's Disease
publication
Author Information
Author(s): Burger Wessel A.C., Sexton Patrick M., Christopoulos Arthur, Thal David M.
Conclusion
The clinical trial of xanomeline for treating Alzheimer’s disease was incorrectly described as a phase 3 trial when it was actually a phase 2 trial.
Supporting Evidence
- Xanomeline was the first molecule developed by Lilly for Alzheimer's treatment.
- The program was discontinued after a phase 2 trial due to unacceptable side effects.
Takeaway
There was a mistake in saying that xanomeline was tested in a phase 3 trial for Alzheimer's when it was really just a phase 2 trial.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website